chevron_leftBack
As of 13 June 2026, Skye Bioscience, Inc. has a market cap of $31.41M USD, ranking #33922 globally and #4763 in the United States.
It ranks #3064 in the Healthcare sector, and #1046 in the Drug Manufacturers - General industry.
Key Stats
Market Cap
$31.41MUSD
Enterprise Value
$5.8MUSD
EBITDA (TTM)
-$57.44MUSD
Net Income (TTM)
-$55.92MUSD
PB Ratio
1.6
Company Profile
Country (HQ)
Sector
Healthcare
Industry
Drug Manufacturers - General
CEO
Punit Dhillon
open_in_new
Employees
12
Founded
2012
Website
skyebioscience.com
open_in_new
warningChart data may be delayed
| 1d | 1w | 1m | 3m | 6m | 1y |
|---|---|---|---|---|---|
| -3.9% | -1.8% | 53% | -12% | -43% | -54% |
News
Loading...
SKYE Analyst Forecasts
Loading...
Markets
| Exchange | Ticker | Price |
|---|---|---|
|
SKYE
Skye Bioscience Inc Ordinary Shares
ISIN: US83086J2006
Shares Out.:
Shares Outstanding:
35.144M1
Shares Float:
22.967M2
TV:
TradingView:
SA:
Stock Analysis:
YF:
Yahoo Finance:
GF:
Google Finance:
NQ:
NASDAQ:
BA:
Barron's:
MS:
Morningstar:
|
0.8941 USD |
1Market cap is calculated using shares outstanding.
2Float shares are publicly tradable shares, excluding insider-held stock.
About Skye Bioscience, Inc.
Skye Bioscience, Inc., a clinical-stage biotechnology company, focuses on developing molecules that modulate G-protein-coupled receptors (GPCRs) to treat obesity, overweight, and metabolic diseases. Its lead product candidate is nimacimab, a peripherally restricted negative allosteric modulating antibody targeting cannabinoid receptor 1, a key GPCR involved in metabolic regulation. The company was formerly known as Emerald Bioscience, Inc. and changed its name to Skye Bioscience, Inc. in January 2021. Skye Bioscience, Inc. is headquartered in San Diego, California.
Similar Companies
| Name |
Market Cap (USD)
diff.
|
PE | Country |
|---|---|---|---|
NYSE: LLY
|
$761.68B
2M%
|
38.1
|
|
NYSE: JNJ
|
$547.28B
2M%
|
26.4
|
|
NYSE: ABBV
|
$360.63B
1M%
|
97.4
|
|
NYSE: MRK
|
$274.03B
872K%
|
15.1
|
|
NYSE: PFE
|
$149.38B
476K%
|
19.5
|
|
NYSE: BMY
|
$117.58B
374K%
|
16.8
|
| Name |
Market Cap (USD)
diff.
|
PE | Country |
|---|---|---|---|
SIX: RO
|
$321.52B
1M%
256.25B CHF
|
19.9
|
|
LSE: AZN
|
$288.84B
920K%
215.59B GBP
|
27.6
|
|
SIX: NOVN
|
$274.65B
874K%
218.9B CHF
|
20.5
|
|
CPH: NOVO-B
|
$181.82B
579K%
1.18T DKK
|
11.5
|
|
EPA: SAN
|
$110.1B
350K%
95.26B EUR
|
19.9
|
|
LSE: GSK
|
$108.46B
345K%
80.96B GBP
|
14.6
|
chevron_leftBack